These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
65 related articles for article (PubMed ID: 1054895)
1. The diagnostic significance of parabasal cells. II. Rate of their disappearance and reappearance under estrogen administration and withdrawal. Batrinos M; Eustratiades M Acta Cytol; 1975; 19(2):100-2. PubMed ID: 1054895 [TBL] [Abstract][Full Text] [Related]
2. The diagnostic significance of parabasal cells. I. Correlation with the clinical diagnosis in 209 patients. Batrinos M; Eustratiades M Acta Cytol; 1975; 19(2):97-9. PubMed ID: 1054902 [TBL] [Abstract][Full Text] [Related]
3. A comparative study of the estrogenic potential of two synthetic estrogens (mestranol and ethinylestradiol). Teter J; Stupnicki R Acta Cytol; 1971; 15(2):167-70. PubMed ID: 5282948 [TBL] [Abstract][Full Text] [Related]
4. Vaginal cytology in endocrinopathies. Efstratiades M; Panitsa-Faflia C; Batrinos M Acta Cytol; 1983; 27(4):421-5. PubMed ID: 6576541 [TBL] [Abstract][Full Text] [Related]
5. An open-label randomized trial to determine the most effective regimen of vaginal estrogen to reduce the prevalence of atrophic changes reported in postmenopausal cervical smears. Bateson DJ; Weisberg E Menopause; 2009; 16(4):765-9. PubMed ID: 19407678 [TBL] [Abstract][Full Text] [Related]
6. Endometrial pattern in patients with primary hypoestrogenic amenorrhea receiving estrogen replacement therapy. Van Campenhout J; Choquette P; Vauclair R Obstet Gynecol; 1980 Sep; 56(3):349-55. PubMed ID: 7422173 [TBL] [Abstract][Full Text] [Related]
7. Postmenopausal vaginal atrophy correlates with decreased estradiol and body mass index and does not depend on the time since menopause. Repse-Fokter A; Takac I; Fokter SK Gynecol Endocrinol; 2008 Jul; 24(7):399-404. PubMed ID: 18645712 [TBL] [Abstract][Full Text] [Related]
8. Cytohormonal and morphological alterations in cervicovaginal smears of postmenopausal women on hormone replacement therapy. Gupta S; Kumar N; Singhal N; Manektala U; Jain S; Sodhani P Diagn Cytopathol; 2006 Oct; 34(10):676-81. PubMed ID: 16955474 [TBL] [Abstract][Full Text] [Related]
9. Effect of estradiol valerate and levonorgestrel on vaginal health. Manonai J; Chittacharoen A; Theppisai U Eur J Obstet Gynecol Reprod Biol; 2004 Aug; 115(2):190-3. PubMed ID: 15262354 [TBL] [Abstract][Full Text] [Related]
10. Goblet-like cells in atrophic vaginal smears and their histologic correlation. Possible confusion with endocervical cells. Koike N; Higuchi T; Sakai Y Acta Cytol; 1990; 34(6):785-8. PubMed ID: 1701599 [TBL] [Abstract][Full Text] [Related]
11. Amenorrhea and endometrial atrophy with continuous oral estrogen and progestogen therapy in postmenopausal women. Magos AL; Brincat M; Studd JW; Wardle P; Schlesinger P; O'Dowd T Obstet Gynecol; 1985 Apr; 65(4):496-9. PubMed ID: 2984616 [TBL] [Abstract][Full Text] [Related]
12. Intravaginal dehydroepiandrosterone (Prasterone), a physiological and highly efficient treatment of vaginal atrophy. Labrie F; Archer D; Bouchard C; Fortier M; Cusan L; Gomez JL; Girard G; Baron M; Ayotte N; Moreau M; Dubé R; Côté I; Labrie C; Lavoie L; Berger L; Gilbert L; Martel C; Balser J Menopause; 2009; 16(5):907-22. PubMed ID: 19436225 [TBL] [Abstract][Full Text] [Related]
13. Endometrial morphology during hormone replacement therapy with estradiol gel combined to levonorgestrel-releasing intrauterine device or natural progesterone. Suvanto-Luukkonen E; Malinen H; Sundström H; Penttinen J; Kauppila A Acta Obstet Gynecol Scand; 1998 Aug; 77(7):758-63. PubMed ID: 9740525 [TBL] [Abstract][Full Text] [Related]
14. The effect of transdermal and vaginal estrogen therapy on markers of postmenopausal estrogen status. Gupta P; Ozel B; Stanczyk FZ; Felix JC; Mishell DR Menopause; 2008; 15(1):94-7. PubMed ID: 17882008 [TBL] [Abstract][Full Text] [Related]
15. Estrogens and the urogenital tract. Studies on steroid hormone receptors and a clinical study on a new estradiol-releasing vaginal ring. Smith P Acta Obstet Gynecol Scand Suppl; 1993; 157():1-26. PubMed ID: 8393609 [TBL] [Abstract][Full Text] [Related]
16. [Long-term therapy using depot estrogens in the climacteric syndrome]. Cupr Z; Druckmüller V; Kucera F Zentralbl Gynakol; 1969 Jul; 91(27):873-80. PubMed ID: 5363471 [No Abstract] [Full Text] [Related]
17. Influence of modified transdermal hormone replacement therapy on the concentrations of hormones, growth factors, and bone mineral density in women with osteopenia. Stanosz S; Zochowska E; Safranow K; Sieja K; Stanosz M Metabolism; 2009 Jan; 58(1):1-7. PubMed ID: 19059524 [TBL] [Abstract][Full Text] [Related]
18. Randomized, multicenter, double-blind, placebo-controlled trial to evaluate the efficacy and safety of synthetic conjugated estrogens B for the treatment of vulvovaginal atrophy in healthy postmenopausal women. Simon JA; Reape KZ; Wininger S; Hait H Fertil Steril; 2008 Oct; 90(4):1132-8. PubMed ID: 18053998 [TBL] [Abstract][Full Text] [Related]
19. The use of cytological examination of vaginal smears (CEVS) in the selection of rabbits for superovulation. Tsiligianni T; Saratsi A; Besenfelder U; Anastasiadis A; Vainas E; Saratsis P; Brem G Theriogenology; 2004 Apr; 61(6):989-95. PubMed ID: 15036989 [TBL] [Abstract][Full Text] [Related]
20. A comparison of raloxifene and calcium plus vitamin D on vaginal atrophy after discontinuation of long-standing postmenopausal hormone therapy in osteoporotic women. A randomized, masked-evaluator, one-year, prospective study. Checa MA; Garrido A; Prat M; Conangla M; Rueda C; Carreras R Maturitas; 2005 Sep; 52(1):70-7. PubMed ID: 16143228 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]